Life Sciences Tools and Services
Company Overview of SomaLogic, Inc.
SomaLogic, Inc. operates as a life science tools and clinical diagnostics company. It offers Slow Off-rate Modified Aptamer (SOMAmer) technology to develop and commercialize proteomic life sciences research tools for the research community; and discover, develop, and commercialize life science research tools and breakthrough clinical diagnostic products that transform healthcare. The company also provides SOMAscan assay, a protein biomarker discovery tool for the life sciences community; SOMAmer reagents, which enable a host of life science applications, including quantitative measurement of individual proteins, histochemistry of frozen tissue samples, flow cytometry, and affinity purificati...
2945 Wilderness Place
Boulder, CO 80301
Founded in 1999
Key Executives for SomaLogic, Inc.
Chief Executive Officer and Director
Founder and Chairman of the Board
Chief Medical Officer Emertius
Compensation as of Fiscal Year 2015.
SomaLogic, Inc. Key Developments
SomaLogic and Otsuka Pharmaceutical Extends Initial Collaboration Agreement to Continue the Development of Several Somamer Therapeutics
Aug 11 15
SomaLogic announced that Otsuka Pharmaceutical has extended its initial collaboration agreement with SomaLogic to continue the development of several SOMAmer therapeutics. Specific projects and financial terms in the extended agreement were not disclosed. SomaLogic is the recognized leader in the development and application of advanced aptamer technologies. The company has designed its proprietary SOMAmer reagents to combine the wide target range of antibodies with the consistency and reproducibility of traditional aptamers. The chemical addition of protein-like side chains to the nucleic acid bases that comprise a SOMAmer molecule results in the ability to discover molecules that bind specifically and tightly to virtually any targeted protein. These properties allow SOMAmer molecules to be used in virtually any laboratory or clinical application that currently uses monoclonal antibodies, including therapeutics. This property, along with other unique characteristics, makes SOMAmer candidates attractive for novel therapeutic discovery and development.
SomaLogic, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 04:15 PM
Jun 18 15
SomaLogic, Inc. Presents at Cantor Fitzgerald's Inaugural Healthcare Conference, Jul-08-2015 04:15 PM. Venue: Le Parker Meridien Hotel, 119 W. 56th Street, New York, NY 10019, United States. Speakers: Byron D. Hewett, Chief Executive Officer and Director.
SomaLogic, Inc. Announces Agreement to Place SOMAscan Proteomics Assay at Manitoba Centre for Proteomics and Systems Biology
Feb 4 15
SomaLogic, Inc. announced that the University of Manitoba's Centre for Proteomics and Systems Biology (MCPSB) is the first SOMAscan™ assay 'Early Access' site outside of the United States. It is expected that the assay will be installed and fully functional at the Centre by the middle of 2015, under the leadership of Director John A. Wilkins, Ph.D. SOMAmer® (Slow Off-rate Modified Aptamer) reagents, which are at the center of SomaLogic's proteomics platform, are a new class of superior protein-binding reagents that combine the best properties of both monoclonal antibodies and traditional aptamers. The SOMAscan assay, which incorporates 1,129 different SOMAmer reagents, can efficiently, accurately, and rapidly measures proteins across a wide range of concentrations in small volumes of multiple biological sample types. SomaLogic is continuing to expand access to its SOMAscan assay through its placement in leading academic research centers. Current sites, in addition to MCPSB, include Massachusetts General Hospital, the University of Pennsylvania, the US National Institutes of Health, and the University of Colorado Denver, with several more expected to be announced in the coming months.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 17, 2014